JUN 27, 2018 7:06 AM PDT

Cannabis-Based Therapy Drug For The Treatment of Epilepsy

WRITTEN BY: Nouran Amin

A drug derived from marijuana has been the first to be approved by the U.S. Food and Drug Administration for the treatment epilepsy.

The drug, which will be marketed under the name Epidiolex, will specifically seek to treat two serious forms of epilepsy: Lennox-Gastaut syndrome and Dravet syndrome. These syndromes are known to begin in childhood and persist in adulthood.

Epidiolex is made from purified cannabidiol (CBD), a compound present in the cannabis plant. CBD is known to have medicinal effects, however, it does not exert the mind-altering high that results from THC, the primary psychoactive component of marijuana.

"This approval serves as a reminder that advancing sound development programs that properly evaluate active ingredients contained in marijuana can lead to important medical therapies," explains FDA Commissioner Scott Gottlieb.

A few states have approved CBD oil in the treatment of intractable epilepsy or seizure disorders.

A drug made from a derivative of marijuana has been approved for patients with certain forms of epilepsy. Blaine Harrington III/Getty Images

"Our biggest concerns with the artisanal [or supplement] versions of CBD were related to the consistency," Carson says. "We can't guarantee the consistency."

Carson believes he will likely prescribe Epidiolex in the future. "I'm always excited about the potential for a new therapy that has been well-studied and has a great potential for benefit," says Carson.

Multiple investigators are examining the efficacy of CBD in the treatment of psychiatric conditions. For example, a clinical study is now underway to examine whether CBD can effectively treat post-traumatic stress disorder and alcohol use disorder. Additionally, another clinical study will test whether CBD could be a potential treatment to help prevent relapse in opioid abusers.

Such approval of Epidiolex will help open the doors to more studies on CBD, which will lift a regulatory hurdle. As of now, the Drug Enforcement Administration placed CBD in the heroin and LSD category as a Schedule 1 substance which mean that these drugs have no medical use potential and only a high abuse substance.

According to Dr. Douglas Throckmorton, deputy director of regulatory programs at the FDA's Center for Drug Evaluation and Research , when CBD is approved as a medical use drug- the DEA will change its classification.

"The DEA will need to make a different scheduling decision for CBD...because it now has an accepted medical use," explains Throckmorton.

About the Author
  • Nouran earned her BS and MS in Biology at IUPUI and currently shares her love of science by teaching. She enjoys writing on various topics as well including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
OCT 12, 2020
Microbiology
Researchers May Have Found a Way to Cure Rotavirus Infections
OCT 12, 2020
Researchers May Have Found a Way to Cure Rotavirus Infections
Rotaviruses are very contagious. They are the most common cause of diarrhea in children and are estimated to cause about ...
OCT 20, 2020
Cannabis Sciences
Should Cannabis Doses Be Standardized?
OCT 20, 2020
Should Cannabis Doses Be Standardized?
Should cannabis and its compounds such as tetrahydrocannabinol (THC), the psychoactive compound in cannabis, come in sta ...
OCT 27, 2020
Cardiology
Boron Could Prevent Myocardial Fibrosis and Assist in Recovery
OCT 27, 2020
Boron Could Prevent Myocardial Fibrosis and Assist in Recovery
When you pass by the nutrition section at the local grocery store, there is a chance you’ll come across row upon r ...
OCT 29, 2020
Cardiology
Treating Cardiovascular Calcification at the Source
OCT 29, 2020
Treating Cardiovascular Calcification at the Source
The term cardiovascular disease covers a broad array of health problems. Everyone tends to think of heart attacks or hyp ...
OCT 23, 2020
Drug Discovery & Development
Common Asthmatic Treatments Increase Risk of Bone Fractures
OCT 23, 2020
Common Asthmatic Treatments Increase Risk of Bone Fractures
A study published in the journal Thorax found that taking steroid inhalers or tablets for asthma treatment to control fl ...
NOV 22, 2020
Cannabis Sciences
Synthetic Cannabinoids Linked to Increased Deaths in Older Patients with COPD
NOV 22, 2020
Synthetic Cannabinoids Linked to Increased Deaths in Older Patients with COPD
Researchers from St. Michael’s Hospital in Toronto have found that two synthetic cannabinoids available on prescri ...
Loading Comments...